TY - JOUR
T1 - Renal osteodystrophy
AU - McCarthy, J. T.
AU - Kumar, R.
N1 - Funding Information:
This work was supported by the U.S. Dept. of Energy, Basic Energy Sciences, Div. of Materials Science.
PY - 1990
Y1 - 1990
N2 - Renal osteodystrophy is a complex disorder which can be divided into five distinct bone histologic subtypes: mild bone disease, hyperparathyroid bone disease, mixed bone disease, osteomalacia, and low-turnover bone disease. Hyperparathyroidism develops in renal failure due to two principal abnormalities: 1,25(OH)2D3 deficiency and hyperphosphatemia. Treatment of these problems is important in order to prevent hyperparathyroidism. Most cases of osteomalacia, mixed bone disease, and low-turnover bone disease are influenced by aluminum status and parathyroid hormone. Aluminum-associated bone disease can be treated with termination of aluminum exposure and/or deferoxamine therapy. Numerous diagnostic pitfalls exist in the evaluation of renal osteodystrophy, and the bone biopsy is extremely important to avoid these problems and plan proper therapy.
AB - Renal osteodystrophy is a complex disorder which can be divided into five distinct bone histologic subtypes: mild bone disease, hyperparathyroid bone disease, mixed bone disease, osteomalacia, and low-turnover bone disease. Hyperparathyroidism develops in renal failure due to two principal abnormalities: 1,25(OH)2D3 deficiency and hyperphosphatemia. Treatment of these problems is important in order to prevent hyperparathyroidism. Most cases of osteomalacia, mixed bone disease, and low-turnover bone disease are influenced by aluminum status and parathyroid hormone. Aluminum-associated bone disease can be treated with termination of aluminum exposure and/or deferoxamine therapy. Numerous diagnostic pitfalls exist in the evaluation of renal osteodystrophy, and the bone biopsy is extremely important to avoid these problems and plan proper therapy.
UR - http://www.scopus.com/inward/record.url?scp=0025363829&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025363829&partnerID=8YFLogxK
U2 - 10.1016/s0889-8529(18)30339-6
DO - 10.1016/s0889-8529(18)30339-6
M3 - Review article
C2 - 2192869
AN - SCOPUS:0025363829
SN - 0889-8529
VL - 19
SP - 65
EP - 93
JO - Endocrinology and Metabolism Clinics of North America
JF - Endocrinology and Metabolism Clinics of North America
IS - 1
ER -